Single dose vaccination with TNX-801 protects animals from a lethal challenge with monkeypox, the causative agent of mpox TNX ...

Tonix Pharmaceuticals (TNXP) stock gains as the company posts peer-reviewed data for pain drug TNX-102 and new data for mpox ...

TNX-801 is up to 100,000-fold less virulent than live smallpox vaccine strains and a single dose provides robust immunogenicity and protection against mpox and rabbitpox (more than one year) in ...

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) saw its stock rise 2% after unveiling new preclinical findings for its ...

Tonix Pharmaceuticals (NASDAQ:TNXP) announced on Monday an addition to the broad-market Russell 3000 Index and an automatic inclusion in the small-cap Russell 2000 Index. Shares were +0.32% pre-market ...

Tonix Pharmaceuticals (NASDAQ: TNXP) , a fully integrated biopharmaceutical company, announced that Dr. Sina Bavari, Executive Vice President of Infe ...

Read about Tonix Pharmaceuticals Holding Corp (TNXP:XNAS) stock and today's latest news and financial updates.

Tonix Pharmaceuticals (NASDAQ: TNXP) , a fully integrated biotech company, announced its inclusion in the Russell 3000® and Russell 2000® Indexes fol ...

Tonix Pharmaceuticals has filed a registration statement to sell up to $500 million in securities. The company's lead drug candidate is for the management of fibromyalgia pain.

Tonix Pharmaceuticals appoints Jim Hunter to its Board, enhancing commercial strategy ahead of TNX-102 SL's potential fibromyalgia launch.

Tonix Pharmaceuticals Holding Corp.* Tonix is a fully-integrated biotechnology company focused on transforming therapies for pain management and vaccines for public health challenges.